Aparna H. Kesarwala, M.D., Ph.D.

Assistant Clinical Investigator

Radiation Oncology Branch

NCI/CCR

Building 10-CRC, Room B2-3500
Bethesda, MD 20892-1682

301-496-5457

aparna.kesarwala@nih.gov

Research Topics

Dr. Kesarwala's research interests include molecular imaging, DNA repair pathways, and cancer cell metabolism. She is involved in the development of novel molecular imaging agents relevant to the response of tumors to radiation therapy. She also studies pre-clinical radiation modifiers and the interaction of DNA repair pathways and radiation response. Clinically, Dr. Kesarwala treats all types of cancers commonly treated with radiation therapy, including lung and breast cancers. She is board certified in radiation oncology by the American Board of Radiology.

Biography

Dr. Kesarwala received an AB degree in chemistry summa cum laude from Princeton University and medical and graduate degrees from the Washington University School of Medicine. She completed internship at Yale-New Haven Hospital and radiation oncology residency at the National Cancer Institute/National Capital Consortium. Following the completion of her training, she became an Assistant Clinical Investigator in the Radiation Oncology Branch of the NCI.

Selected Publications

  1. Kesarwala AH, Ko CJ, Ning H, Xanthopoulos E, Haglund KE, O'Meara WP, Simone CB 2nd, Rengan R. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer. 2015;16(3):237-44.

  2. Bullok KE, Maxwell D, Kesarwala AH, Gammon S, Prior JL, Snow M, Stanley S, Piwnica-Worms D. Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry. 2007;46(13):4055-65.

  3. Kesarwala AH, Samrakandi MM, Piwnica-Worms D. Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. Cancer Res. 2009;69(3):976-83.

  4. Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang KY, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis. 2012;15(3):289-95.

  5. Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253-7.


This page was last updated on June 15th, 2017